Blockchain Registration Transaction Record

Oragenics Partners with Sterling Pharma for Concussion Treatment Development

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002, targeting concussions, marking a key step towards Phase IIb trials. Learn more about this innovative treatment.

Oragenics Partners with Sterling Pharma for Concussion Treatment Development

This news is significant as it highlights the advancement of a potential breakthrough treatment for concussions, a condition with limited therapeutic options. The partnership between Oragenics and Sterling Pharma Solutions not only accelerates the development of ONP-002 but also reinforces the importance of domestic manufacturing in the biotech sector. For patients suffering from concussions and related conditions, this represents hope for more effective treatments in the near future.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xfd7087e749108c4a2888626820ab5bb1dff1f6757d415c4e3e04a319ff91bf45
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprinthealxuGG-d01b509b9b9c1642125f2ecbf06bfbec